Fig. 4.

The ATX/LPA/LPARs axis as a potential therapeutic target for MDs. Muscle degeneration due to inflammation and fibrosis is the most influencing issue on muscle performance in MDs. The regulation of inflammation and fibrogenesis is the most attractive way to fight MDs. LPA induces pro-fibrotic factors, cytokines, and chemokines. We propose that the use of LPARs antagonists or inhibitors of ATX activity could attenuate the generation of these molecules, decreasing ECM protein deposition and the continued presence of immune and ECM-producing cells, therefore improving muscle regeneration and performance. Created with biorender.com